Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
2.
Indian J Med Sci ; 2011 June; 65(6) 243-249
Article in English | IMSEAR | ID: sea-145615

ABSTRACT

Purpose: One of the features of homozygous sickle cell disease (HbSS) is the impaired elasticity of the erythrocyte membrane that could impede microcirculatory blood flow and cause hypoxia and tissue damage. We investigated the effect of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor that inhibits the breakdown of cyclic guanosine monophosphate (cGMP) resulting in vasodilatation, on the elasticity of HbSS erythrocyte. Materials and Methods: Blood samples from ten HbSS patients in steady state was exposed to different doses (5, 10, 20, and 40 μg/mL) of sildenafil and the elasticity of the erythrocytes measured at native hematocrit with the BioProfiler. An equal number of subjects with normal hemoglobin (HbAA) served as the control group. Results: There was a marginal increase in elasticity with 5 μg/mL of the drug and this became significant (P < 0.05) with the 10 μg/mL dose. Thereafter, gradual nonsignificant decreases were observed with the 20 and 40 μg/mL doses. A similar trend was observed for the control group. The elasticity values for the HbSS subjects at native hematocrit were significantly (P < 0.05) less when compared with the corresponding concentrations for the HbAA controls. This was reversed at a corrected hematocrit of 45%. Conclusion: The result of this study shows that sildenafil caused an initial increase in erythrocyte membrane elasticity in both HbSS and HbAA subjects, and this later decreased with increasing concentration of the drug possibly due to the dual effect of cyclic adenosine monophosphate (cAMP).


Subject(s)
Adult , Anemia, Sickle Cell/epidemiology , Anemia, Sickle Cell/drug therapy , Cyclic AMP/physiology , Cyclic GMP/physiology , Erythrocyte Deformability/drug effects , Homozygote , Humans , Piperazines/therapeutic use , Purines/therapeutic use , Sulfones/therapeutic use , West Indies/epidemiology , Young Adult
3.
J. bras. pneumol ; 34(6): 412-419, jun. 2008.
Article in English, Portuguese | LILACS | ID: lil-485902

ABSTRACT

O nitric oxide (NO, óxido nítrico) é um mediador endógeno vasoativo que contribui para a homeostase vascular pulmonar. O NO é produzido por três isoformas das nitric oxide synthases (NOS, óxido nítrico sintases)-NOS neuronial (nNOS); NOS induzida (iNOS); e NOS endotelial (eNOS)-estando as três presentes no pulmão. Estudos que utilizaram inibidores farmacológicos ou camundongos knockout têm demonstrado que o NO derivado da eNOS desempenha importantes papéis ao modular o tônus vascular pulmonar e atenuar a hipertensão pulmonar. Por outro lado, estudos focados no papel da iNOS têm mostrado que essa isoforma contribui para a fisiopatologia da lesão pulmonar aguda e da síndrome do desconforto respiratório agudo. Esta revisão objetivou delinear o papel desempenhado pelo NO no controle da circulação pulmonar, tanto em condições fisiológicas como fisiopatológicas. Além disso, revisamos as evidências de que a via L-arginina-NO-guanosina monofosfato cíclico seja um importante alvo farmacológico para a terapia de doenças vasculares pulmonares.


Nitric oxide (NO) is an endogenous vasoactive compound that contributes to pulmonary vascular homeostasis and is produced by three nitric oxide synthase (NOS) isoforms-neuronal NOS (nNOS); inducible NOS (iNOS); and endothelial NOS (eNOS)-all three of which are present in the lung. Studies using pharmacological inhibitors or knockout mice have shown that eNOS-derived NO plays an important role in modulating pulmonary vascular tone and attenuating pulmonary hypertension. However, studies focusing on the role of iNOS have shown that this isoform contributes to the pathophysiology of acute lung injury and acute respiratory distress syndrome. This review aimed at outlining the role played by NO in the control of pulmonary circulation, both under physiological and pathophysiological conditions. In addition, we review the evidence that the L-arginine-NO-cyclic guanosine monophosphate pathway is a major pharmacological target in the treatment of pulmonary vascular diseases.


Subject(s)
Animals , Humans , Mice , Hypertension, Pulmonary/physiopathology , Nitric Oxide/physiology , Pulmonary Circulation/physiology , Arginine/physiology , Clinical Trials as Topic , Cyclic GMP/physiology , Mice, Knockout , Nitric Oxide Synthase Type I/metabolism , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide/biosynthesis
4.
Article in English | IMSEAR | ID: sea-55610

ABSTRACT

Two enzyme inhibitors namely L-NAME, a nitric oxide synthase (NOS) inhibitor and methylene blue, a guanylate cyclase inhibitor, were used to elucidate whether N-alpha-tosyl L-arginine methyl ester (TAME)-induced contractions in toad intestinal rings in vitro are mediated through a nitric oxide (NO)- cyclic GMP (c-GMP) pathway. Moreover, a NO precursor, L-arginine was also used to investigate its effect on TAME-induced contractions. Our findings provide evidence that TAME-induced contractions have both an endothelium-dependent and an endothelium-independent component. Based on our findings we now propose that TAME induced contraction involves an endothelium-dependent component mediated through NO and c-GMP.


Subject(s)
Animals , Bufonidae , Cyclic GMP/physiology , Endothelium, Vascular/physiology , Ileum/blood supply , Methylene Blue/pharmacology , Muscle Contraction/drug effects , Muscle, Smooth/blood supply , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/physiology , Tosylarginine Methyl Ester/pharmacology
5.
6.
Acta cient. venez ; 48(3): 145-53, 1997.
Article in Spanish | LILACS | ID: lil-228498

ABSTRACT

During the last years there have been major advances in the knowledge of cyclic nucleotide phosphodiesterases. Particularly, referred to the presence of multiple different isozymes. Seven different phosphodiesterase gene families, have been described in mammalian tissues, containing several distinct genes, most of them expressed in different tissues as functionally unique splice variants. This article includes various aspects of the currently accepted nomenclature, structure and function of each family of phosphodiesterases. Finally, a brief discussion of the presence and role of these enzymes in the cell proliferation and differentiation processes, in parasites of the Trypanosmatidae family, is provided


Subject(s)
Animals , 2',3'-Cyclic-Nucleotide Phosphodiesterases , Cyclic AMP , Cyclic GMP , Isoenzymes , Trypanosomatina/enzymology , 2',3'-Cyclic-Nucleotide Phosphodiesterases/chemistry , 2',3'-Cyclic-Nucleotide Phosphodiesterases/classification , 2',3'-Cyclic-Nucleotide Phosphodiesterases/physiology , Cell Differentiation , Cyclic AMP/agonists , Cyclic AMP/physiology , Cyclic GMP/agonists , Cyclic GMP/physiology , Terminology , Trypanosomatina/cytology
7.
Biol. Res ; 29(3): 319-24, 1996.
Article in English | LILACS | ID: lil-228524

ABSTRACT

Invertebrate visual transduction involves a second messenger cascade process that leads to an increase in membrane conductance. The identity of the second messenger that gates the light-dependent channels is presently a major focus of attention. Cyclic GMP, inositol trisphosphate and Ca2+ are the most likely candidates for being such a messenger in the species studied so far. Here we review the available evidence for each of these molecules


Subject(s)
Animals , Light Signal Transduction/physiology , Photoreceptor Cells, Invertebrate/physiology , Second Messenger Systems/physiology , Calcium Channels/physiology , Cyclic GMP/physiology , Inositol 1,4,5-Trisphosphate/physiology
SELECTION OF CITATIONS
SEARCH DETAIL